Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor NK Cells and Low-dose IL-2 for Relapsed AML After Allo-HSCT
NCT06641648Phase 1Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous activated and expanded natural killer cells in acute myeloid leukemia (AML), sponsored by Peking University First Hospital. Primary endpoints: Dose Limiting Toxicities at 1 month and Treatment-related adverse events at 1 month. Started Nov 2025; status: recruiting.
02
Drugs
autologous activated and expanded natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06641648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641648.